Nanobiotix (NASDAQ:NBTX) Shares Gap Down - What's Next?

Key Points

• Nanobiotix shares experienced a significant gap down, opening at $14.93 after closing at $16.44, and currently trading at $15.13 with a volume of 27,538 shares.
• Equities analysts have mixed ratings on Nanobiotix, with HC Wainwright issuing a "buy" rating while Leerink Partners set a target price of $14.00, against a consensus rating of "Moderate Buy" and a price target of $11.00.
• Institutional ownership represents 38.81% of Nanobiotix stock, with Millennium Management LLC recently acquiring a new position valued at approximately $39,000.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $16.44, but opened at $14.93. Nanobiotix shares last traded at $15.13, with a volume of 27,538 shares.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on NBTX shares. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Leerink Partners set a $14.00 target price on Nanobiotix in a research note on Thursday, September 18th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Nanobiotix presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Nanobiotix Stock Performance

The stock has a 50 day simple moving average of $8.53 and a 200 day simple moving average of $5.53.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Millennium Management LLC acquired a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 13,452 shares of the company's stock, valued at approximately $39,000. 38.81% of the stock is owned by institutional investors.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.